Multidisciplinary team-working indicators of good practice in the clinical management of EGFR-inhibitor dermatologic toxicities.
Manganoni
Ausilia Maria
AM
Farisoglio
Camillo
C
Ferrari
Vittorio
V
Zaniboni
Alberto
A
Beretta
Giordano
G
Meriggi
Fausto
F
Calzavara-Pinton
Piergiacomo
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D003875:Drug Eruptions / Q000188:drug therapy / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D033183:Interdisciplinary Communication; D007641:Keratolytic Agents / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D010348:Patient Care Team; D020156:Salicylic Acid / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007641:Keratolytic Agents; D066246:ErbB Receptors; D020156:Salicylic Acid; D000068818:Cetuximab